8.3 Post-Mastectomy Reconstruction & Oncoplastic Surgery

Reconstructive Legislation, Timing Paradigms & Surgical Decision-Making

Breast reconstruction following mastectomy represents an essential, restorative component of comprehensive breast cancer survivorship. It restores anatomical symmetry, clothes fit, and body image, mitigating the psychological trauma associated with amputation of the breast.

The Women's Health and Cancer Rights Act of 1998 (WHCRA)

The Women's Health and Cancer Rights Act of 1998 (WHCRA) is a landmark federal law signed into United States legislation to eliminate insurance barriers to breast reconstruction. The WHCRA mandates that any group health plan, commercial insurance company, or health maintenance organization (HMO) that provides coverage for medical and surgical benefits with respect to a mastectomy must also provide coverage for:

1. All stages of reconstruction of the breast on which the mastectomy was performed (including tissue expansion, permanent implant placement, or autologous flap transfers).
2. Surgery and reconstruction of the contralateral (unaffected) breast to produce a symmetrical appearance (including reduction mammaplasty, mastopexy [breast lift], or augmentation mammaplasty).
3. Prostheses (both external breast prostheses and internal implants) and specialized post-mastectomy brassieres.
4. Treatment of physical complications at all stages of mastectomy, including lymphedema (e.g. compression garments, manual lymphatic drainage, physical therapy).

Critical Legal Provisions: WHCRA sets no time limit on when a patient may elect to pursue reconstruction. It applies to group health plans and individual health insurance policies that cover mastectomy; Medicare and Medicaid are not governed by WHCRA, although both generally cover post-mastectomy reconstruction. A patient who underwent mastectomy 10 or 20 years ago retains full federal rights to reconstructive surgery and contralateral symmetry procedures. Breast care nurses serve as essential patient advocates in educating women about their federal protections under the WHCRA.

Reconstructive Timing Paradigms

• Immediate Reconstruction: Initiated simultaneously with the oncologic mastectomy under the same general anesthetic.
  • Advantages: Single surgical event, superior psychological recovery, preservation of the native inframammary fold and skin envelope, and superior aesthetic symmetry.
  • Disadvantages: Longer initial operative time; if adjuvant chemotherapy is required, post-surgical wound complications (infection, skin flap necrosis) can potentially delay systemic treatment.
• Delayed Reconstruction: Performed months to years following the completion of all oncologic therapies (mastectomy, chemotherapy, and radiation therapy).
  • Advantages: Prioritizes oncologic margin clearance and allows uncomplicated delivery of adjuvant therapies; provides the patient with dedicated time to deliberate reconstructive modalities.
  • Disadvantages: Requires multiple separate major operations; irradiated chest wall skin becomes contracted, fibrotic, and inelastic, frequently necessitating autologous flap tissue transfer rather than prosthetic expanders alone.
• Delayed-Immediate Reconstruction (Two-Stage Hybrid): Frequently utilized when post-mastectomy radiation therapy (PMRT) is anticipated. A temporary tissue expander is placed at the time of mastectomy to preserve the skin pocket and inframammary fold. Once final pathology confirms nodal involvement and PMRT is completed, the expander is removed 6 to 12 months post-radiation and replaced with a definitive autologous tissue flap (such as a DIEP flap). This prevents delivering high-dose ionizing radiation directly to a newly transferred vascularized autologous flap.

Prosthetic and Autologous Reconstructive Modalities

Breast reconstruction is divided into two primary surgical categories: prosthetic (implant-based) and autologous tissue (flap) reconstruction.

Prosthetic (Implant-Based) Reconstruction

Prosthetic reconstruction represents approximately 70% to 75% of post-mastectomy reconstructions in the United States, utilizing silicone gel or sterile saline implants.

• Two-Stage Expander-to-Implant Reconstruction:
  • Stage 1: Placement of an empty or partially filled temporary tissue expander equipped with a magnetic or palpable injection port.
  • Expansion Phase: Starting 2 to 3 weeks postoperatively once skin incisions are healed, sterile normal saline is injected percutaneously into the port in clinic (typically 50 to 100 mL every 1 to 2 weeks) until the desired breast volume is attained.
  • Stage 2: After a 2- to 6-month resting period allowing tissue relaxation, the expander is surgically removed and replaced with a permanent cohesive silicone gel or saline breast implant.
• Direct-to-Implant (DTI) Reconstruction: Single-stage placement of a permanent cohesive silicone implant at the time of mastectomy, bypassing tissue expansion. Requires well-perfused, robust mastectomy skin flaps and reliable support from acellular dermal matrix (ADM).
• Anatomical Pocket Selection: Subpectoral vs. Prepectoral:
  • Subpectoral Placement: The tissue expander or implant is inserted beneath the pectoralis major muscle, with the inferior pole supported by a sheet of Acellular Dermal Matrix (ADM) (decellularized human, bovine, or porcine extracellular collagen matrix) serving as an internal hammock. Provides soft-tissue coverage over the upper pole, but can cause animation deformity (involuntary, visible distortion and flattening of the implant whenever the pectoralis major muscle contracts during physical activity) and increased post-op chest wall spasms.
  • Prepectoral Placement: The expander or implant is placed completely superficial to the pectoralis major muscle in the subcutaneous pocket, wrapped circumferentially in ADM. Prepectoral placement completely eliminates animation deformity, preserves the integrity of the pectoral muscle, reduces postoperative pain, and accelerates return to athletic activities. However, it requires impeccably perfused mastectomy skin flaps to prevent flap ischemia and implant exposure.

Autologous Tissue (Flap) Reconstruction

Autologous reconstruction utilizes vascularized tissue harvested from a distant donor site on the patient's body, creating a warm, natural, ptotic breast that ages and fluctuates with body weight.

1. Deep Inferior Epigastric Perforator (DIEP) Flap:
   • The Gold Standard of Autologous Reconstruction.
   • A free tissue transfer utilizing redundant lower abdominal skin and subcutaneous adipose tissue (similar to a cosmetic abdominoplasty panniculectomy).
   • Microvascular Technique: Minute perforating blood vessels arising from the deep inferior epigastric artery and vein are carefully dissected through the rectus abdominis muscle. The vessels are transected and anastomosed under an operating microscope to recipient internal mammary vessels in the chest wall.
   • Anatomical Benefit: The rectus abdominis muscle and anterior rectus fascia are completely preserved. Sparing the abdominal wall musculature drastically reduces donor-site abdominal weakness, bulge, and incisional hernia formation compared to TRAM flaps.
2. Transverse Rectus Abdominis Myocutaneous (TRAM) Flap:
   • Pedicled TRAM: The skin, fat, and an entire rectus abdominis muscle are rotated through a subcutaneous epigastric tunnel into the chest based on the superior epigastric vascular pedicle. Sacrificing the rectus muscle carries a 15% to 30% risk of abdominal hernia, chronic core weakness, and higher rates of partial flap necrosis.
   • Free TRAM: Detached with a small muscle cuff and microvascularly anastomosed; preserves more muscle than pedicled TRAM but remains inferior to the muscle-sparing DIEP flap.
3. Latissimus Dorsi (LD) Myocutaneous Flap:
   • A pedicled flap transferring the latissimus dorsi muscle, thoracodorsal neurovascular bundle, and an overlying skin paddle from the ipsilateral back to the anterior chest wall.
   • Because back tissue yields limited adipose volume, the latissimus dorsi flap is frequently combined with a silicone or saline implant to achieve adequate breast projection. Commonly utilized for salvage reconstruction following radiation necrosis or failed expander reconstruction.
4. Alternative Perforator Flaps (When Abdominal Tissue is Inadequate):
   • Superficial Inferior Epigastric Artery (SIEA) Flap: Abdominal tissue based on superficial vessels, completely avoiding rectus fascial incision; limited by variable superficial vascular anatomy.
   • Gluteal Artery Perforator (GAP) Flaps (S-GAP / I-GAP): Skin and fat harvested from the upper or lower buttock.
   • Transverse Upper Gracilis (TUG) & Profunda Artery Perforator (PAP) Flaps: Tissue harvested from the inner or upper posterior thigh.

Oncoplastic Surgery, Flap Viability Monitoring & Implant Complications

Oncoplastic Breast-Conserving Surgery

Oncoplastic surgery combines the oncologic principles of wide tumor excision with plastic and reconstructive techniques to prevent breast distortion and maximize aesthetic outcomes in patients undergoing breast-conserving surgery (BCS):

• Volume Displacement Techniques: Mobilization, rotation, and advancement of adjacent residual glandular flaps within the breast parenchyma to close the resection defect. Indicated for small-to-moderate tissue deficits (<20% of total breast volume) in women with medium-to-large breasts.
• Volume Replacement Techniques: Transfer of autologous tissue from regional sites outside the breast (e.g. lateral thoracic artery perforator [LTAP] flap or thoracodorsal artery perforator [TDAP] flap) into the lumpectomy defect. Indicated when more than 20% of breast volume is resected or in small breasts where volume displacement would cause severe asymmetry.
• Therapeutic Reduction Mammaplasty: In women with large, macromastic, or pendulous breasts, the cancer is resected within a formal breast reduction pattern (e.g. inferior pedicle or inverted-T Wise pattern). A simultaneous contralateral balancing reduction is performed to achieve cosmetic symmetry, alleviate chronic neck and back strain, and improve quality of life.

Flap Viability Monitoring and Vascular Triage

Following microvascular free tissue transfer (DIEP, free TRAM, GAP), meticulous nursing monitoring every hour for the first 24 to 48 hours is vital to detect acute vascular thrombosis. Vascular compromise occurs in 1% to 4% of free flaps, and emergency re-exploration within a narrow 4- to 6-hour window is required to salvage the flap before irreversible tissue necrosis occurs.

Emergency Nursing Action: If signs of venous congestion (dusky blue color, tense turgor, rapid capillary refill <1 second, instant dark blood) or arterial insufficiency (pale, cold, absent refill, absent bleeding) occur, the nurse must immediately notify the reconstructive surgical team, loosen tight dressings or tape, ensure the patient is warm and normotensive, and prepare for urgent re-exploration in the operating room.

Complications of Prosthetic Implants

• Capsular Contracture: The physiological immune system forms a collagenous fibrous capsule around the foreign implant. In a subset of patients (5% to 15%), an exaggerated fibrotic reaction causes the capsule to progressively thicken and constrict around the device, producing tightness, pain, and spherical deformity. Capsular contracture is categorized using the Baker Classification:
  • Grade I: Breast is completely soft; looks and feels natural.
  • Grade II: Slightly firm to touch, but breast maintains a normal appearance.
  • Grade III: Moderately firm; implant is visibly distorted or elevated.
  • Grade IV: Breast is hard, severely deformed, cold, and chronically painful. Requires surgical intervention (capsulectomy or capsulotomy with implant exchange).
• Breast Implant-Associated Anaplastic Large Cell Lymphoma (BIA-ALCL):
  • A rare peripheral T-cell non-Hodgkin lymphoma that develops in the periprosthetic fluid or capsule surrounding breast implants.
  • Etiology: Strongly associated with macro-textured implant surfaces (which harbor chronic bacterial biofilms that trigger sustained T-cell proliferation and malignant transformation). Confirmed cases overwhelmingly involve textured implants; cases in patients known to have had only smooth implants are exceedingly rare. In 2022 the FDA also reported rare squamous cell carcinoma and other lymphomas in the capsule around breast implants.
  • Clinical Presentation: Manifests as a sudden, late-onset peri-implant seroma (fluid collection) or mass developing years after implantation (median onset 8 to 10 years post-surgery).
  • Diagnostic Workup: Ultrasound-guided fine-needle aspiration of the periprosthetic seroma fluid. The aspirate is sent for cytology, cell block preparation, and immunohistochemistry for CD30 positivity and anaplastic lymphoma kinase (ALK) negativity.
  • Treatment: Complete surgical en bloc resection of the implant and the entire intact fibrous capsule (total capsulectomy). Early-stage disease confined to the capsule is curable with surgical excision alone without systemic chemotherapy.
• Nipple-Areola Reconstruction and 3D Micropigmentation:
  • Final phase of reconstruction, performed 2 to 4 months following breast mound stabilization.
  • Local Skin Flaps: Local dermal-adipose flaps (skate, star, or bell flaps) are elevated and folded to create a projecting nipple papilla.
  • 3D Medical Micropigmentation: Specialized intradermal tattooing using permanent pigments with shading, highlighting, and realistic Montgomery tubercle detailing to replicate the 3D optical appearance of a natural nipple-areolar complex without surgical incisions.